new delhi the technical advisory group tag an independent advisory panel of the world health organisation who has sought additional clarifications from bharat biotech the manufacturer of covaxin in order to conduct a final emergency use listing eul riskbenefit assessment for global use of the vaccinethe world health organisation will meet on wednesday for a final risk benefit assessment for its emergency use listing the tag met on october 26 2021 and decided to seek additional clarifications from the covaxin manufacturers that are needed to conduct a final eul riskbenefit assessment for global use of the vaccine said a who official the technical advisory group had met october 26 and had sought additional details from bharat biotech covaxin has demonstrated 778 percent effectiveness against symptomatic covid19 and 652 percent protection against the new delta variant in june the company had said it concluded the final analysis of covaxin efficacy from phase 3 trials bharat biotechs covaxin and astrazeneca and serum institutes covishield are the two widely used vaccines in indialast week the who had said that the timeframe for it emergency use listing procedure is dependant on how quickly a manufacturing company producing the desired vaccine is able to provide the data required for who to evaluate the vaccines efficacy safety qualityand its suitable for low and middleincome countries meanwhile indias cumulative vaccination coverage crossed 107 crorethe who has so far approved covid19 vaccines of pfizerbiontech astrazenecask bioserum institute of india johnson 7 johnson janssen moderna and sinopharm for emergency usewith inputs from agencies